We are monitoring the impact of COVID-19 & Recession alarm on Europe Diabetic Retinopathy Market Get in touch with us for detailed analysis Know More
Share on

Europe Diabetic Retinopathy Market Research Report - Segmented By Treatment Type, Indication, End User, By Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 877
Pages: 143

European Diabetic Retinopathy Market Size (2022 to 2027)

The size of the Diabetic Retinopathy Market in Europe has been estimated at USD 1.34 billion in 2022. It is projected to reach USD 1.84 billion by 2027, at a CAGR of 6.55% during the forecast period.

Diabetic retinopathy is a medical condition which damages the retina and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the epidemic at its initial stage.

Growth enhancing factors are government initiatives, abundant R&D activities, and skill set enhancement of healthcare providers. Such supportive initiatives, coupled with rising awareness among patients, are anticipated to result in lucrative growth. Treatment of diabetic retinopathy is expected to gain patients' willingness for treatment by introducing advanced technology and reducing pain by using laser procedures with quick recovery time.

The adoption of sedentary lifestyles and changes in food habits is driving the demand of the market. An increasing number of diabetic patients is also considered a significant factor propelling the growth of the European diabetic retinopathy market. Growing awareness over the availability of drugs for different diseases is accelerating the demand of the market. In addition, the rise in the geriatric population and increasing incidences of blindness due to damage of blood vessels in the retina is gearing up the need of the market. Also, the growing number of surgical treatment procedures is prompting the growth of this market in Europe.

Growth opportunities for the market lie in the emergence of the latest technological developments and innovative devices in favor of the end-user. In addition, increasing concern towards health among individuals, the rise in the knowledge over the treatment procedures, and the availability of trained physicians are leveraging the market's growth. Furthermore, increasing the construction activities of hospitals with the latest equipment is fueling the demand of the market.

However, fluctuations in the production rate of the devices in the medical sector and the cost of installation and maintenance of the equipment is a bit expensive are slowly hampering the growth of the diabetic retinopathy market. In addition, stringent rules and regulations by the government in approving new products have remained a challenging factor for the market.

This research report on the European diabetic retinopathy market has been segmented and sub-segmented into the following categories:

By Treatment Type:

  • Anti-Vascular Endothelial Growth Factor (VEGF) drug
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy     

By Indication:

  • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Mild
    • Moderate
    • Severe
  • Proliferative Diabetic Retinopathy (PDR) 

By End-User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Based on the region, the European diabetic retinopathy market accounted for a substantial share in the global market in 2020, driven by rising patient awareness levels, particularly in the Western European countries. In addition, increasing support from the government through investments is merely magnifying the growth rate of the UK diabetic retinopathy market.

Many people's increasing incidences of obesity and cardiovascular problems due to their lifestyle are lavishing the diabetic retinopathy market in Spain. In addition, the rise in the funds from both private and public organizations is gearing up the growth rate in the Spain market.

Ongoing research in the biotechnology field is ascribed to bolster the demand of the German diabetic retinopathy market. Growing priority for laser treatment surgeries is also broadening the need of the market in Germany.

Growing demand for low-cost and secure operative surgical procedures is raising the need for diabetic retinopathy in Italy.

People's interest in healthy lifestyles and increasing demand for early diagnosis to have a permanent cure for the diseases is enormously accelerating the diabetic retinopathy market in France.

KEY MARKET PLAYERS:

Companies such as Bayer AG, Pfizer Inc., Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc., and Ampio Pharmaceuticals Inc. are playing a leading role in the North American diabetic retinopathy market.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Type of Treatment                                            

                                5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug                          

                                5.1.2 Intraocular Steroid Injection                           

                                5.1.3 Laser Surgery                         

                                5.1.4 Vitrectomy                             

                5.2 By Indication                                              

                                5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)                      

                                                5.2.1.1 Mild       

                                                5.2.1.2 Moderate            

                                                5.2.1.3 Severe  

                                5.2.2 Proliferative Diabetic Retinopathy (PDR)                    

                5.3 By End Users                                             

                                5.3.1 Hospitals                  

                                5.3.2 Ophthalmic Clinics                               

                                5.3.3 Ambulatory Surgical Centers                           

6. Geographical Analysis                                                              

                                6.1 Introduction                              

                                6.2 U.K                

                                6.3 Spain                             

                                6.4 Germany                     

                                6.5 Italy                               

                                6.6 France                          

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 Bayer AG                                     

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Hoffmann-La Roche ltd                                          

                8.4 Regeneron Pharmaceutical Inc.                                         

                8.5 Novartis AG                                

                8.6 Valeant Pharmaceutical International Inc.                                     

                8.7 Abbott Laboratories Inc.                                       

                8.8 Alimera Science Inc.                                                

                8.9 Ampio Pharmaceuticals Inc.                                

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  1. Europe Diabetic Retinopathy Market, By Region, From 2022 - 2027 (USD Million)
  2. Europe Diabetic Retinopathy Market, By Treatment Type, From 2022 - 2027 (USD Million)
  3. Europe Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2022 - 2027 (USD Million)
  4. Europe Intraocular Steroid Injection Market, By Region, From 2022 - 2027 (USD Million)
  5. Europe Laser Surgery Market, By Region, From 2022 - 2027 (USD Million)
  6. Europe Vitrectomy Market, By Region, From 2022 - 2027 (USD Million)
  7. Europe Diabetic Retinopathy Market, By Indication, From 2022 - 2027 (USD Million)
  8. Europe Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2022 - 2027 (USD Million)
  9. Europe Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2022 - 2027 (USD Million)
  10. Europe Mild Indication Market, By Region, From 2022 - 2027 (USD Million)
  11. Europe Moderate Indication Market, By Region, From 2022 - 2027 (USD Million)
  12. Europe Severe Indication Market, By Region, From 2022 - 2027 (USD Million)
  13. Europe Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2022 - 2027 (USD Million)
  14. Europe Diabetic Retinopathy Market, By End Users, From 2022 - 2027 (USD Million)
  15. Europe Hospitals Market, By Region, From 2022 - 2027 (USD Million)
  16. Europe Ophthalmic Clinics Market, By Region, From 2022 - 2027 (USD Million)
  17. Europe Ambulatory Surgical Centers Market, By Region, From 2022 - 2027 (USD Million)
  18. U.K Diabetic Retinopathy Market, By Treatment Type, From 2022 - 2027 (USD Million)
  19. U.K Diabetic Retinopathy Market, By Indication, From 2022 - 2027 (USD Million)
  20. U.K Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2022 - 2027 (USD Million)
  21. U.K Diabetic Retinopathy Market, By End Users, From 2022 - 2027 (USD Million)
  22. Spain Diabetic Retinopathy Market, By Treatment Type, From 2022 - 2027 (USD Million)
  23. Spain Diabetic Retinopathy Market, By Indication, From 2022 - 2027 (USD Million)
  24. Spain Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2022 - 2027 (USD Million)
  25. Spain Diabetic Retinopathy Market, By End Users, From 2022 - 2027 (USD Million)
  26. Germany Diabetic Retinopathy Market, By Treatment Type, From 2022 - 2027 (USD Million)
  27. Germany Diabetic Retinopathy Market, By Indication, From 2022 - 2027 (USD Million)
  28. Germany Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2022 - 2027 (USD Million)
  29. Germany Diabetic Retinopathy Market, By End Users, From 2022 - 2027 (USD Million)
  30. Italy Diabetic Retinopathy Market, By Treatment Type, From 2022 - 2027 (USD Million)
  31. Italy Diabetic Retinopathy Market, By Indication, From 2022 - 2027 (USD Million)
  32. Italy Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2022 - 2027 (USD Million)
  33. Italy Diabetic Retinopathy Market, By End Users, From 2022 - 2027 (USD Million)
  34. France Diabetic Retinopathy Market, By Treatment Type, From 2022 - 2027 (USD Million)
  35. France Diabetic Retinopathy Market, By Indication, From 2022 - 2027 (USD Million)
  36. France Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2022 - 2027 (USD Million)
  37. France Diabetic Retinopathy Market, By End Users, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample